# A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer

> **NCT06890832** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Jina Pharmaceuticals Inc.** · enrollment: 75 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer, MCRPC

## Interventions

- **DRUG:** 50 mg cabazitaxel
- **DRUG:** 100 mg cabazitaxel
- **DRUG:** 200 mg cabazitaxel

## Key facts

- **NCT ID:** NCT06890832
- **Lead sponsor:** Jina Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-06
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890832, "A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT06890832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*